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Durlng percutaneous coronary revaseularisatiou, intracom- 
nary stents are etfective in the treatment of ahrupt vessel closure 
aud imptuvemeut of suboptimal -asty results, and com- 
pared to balloon augioplasty, they reduce stenosis recurrence. 
Opposing tbese benefits, ubacute thrombosis of stents is associ- 
ated witb a substantial increase in periptocedural morbidity and 
mortality. To review factors associated with stent hrombosis and 
to study the impact of evolving procedural techniques on tbe 
incidence of stent tbronthosis, we reviewed all English articles 
from MEDLfNE (1988 to 1995) with key words “stent” and 
Wtromhosis.” Stem registry data and recent abstracts from 
scientitfc meetings were also reviewed. Factors related to the 
ciiica! settiug, the lesion, tbe steot and the procedural technique 
tbat at&t the risk of stent thrombosis were identified. Sixty 
e&&al studies were reviewed and include &914 patients receiving 
Although the success of percutaneous transluminal coronary 
revascularization has steadily improved over the past two 
decades, abrupt vessel closure in the hours postprocedure and 
restenosis in the months postprocedure remain the major 
limitations. Intracoronary stent placement has gained substan- 
tial recent popularity to address these limitations. In 1987, 
S&wart and colleagues (1) were first to report successful 
implantation of intracoronary stents in patients. Early series 
demonstrated a high rdte of procedural success, though this 
was opposed by an alarmingly high rate of stent thrombosis 
within the first month after revascularization (2). Stent throm- 
bosis quickly became a major concern and prompted wide- 
spread study. 
The mechanisms of stent thrombosis are not fully under- 
stood, but a number of associated factors are intuitive. Intra- 
vascular stents are metallic and thus thrombogenic. Similarly, 
vessel injury during percutaneous revascularization exposes 
underlying collagen and tissue factor, which activate platelets 
and the extrinsic coagulation cascade. These events, as well as 
ruptured plaque and thrombus known to be present in acute 
From the Department of Cardiology and Center for Thrombosis and 
Vascular Biokqy. The Ckvelaitd Clinic Foundation, Cleveland. Ohio. Dr. Mak 
is sxpporkd by a grant from the Ministty of Health, Singapore. 
Mawscript received May ZS,W95; revised manuscript received September 
5, 1995, accepted September 8, 1995. 
: Dr. David 1. Molitemo, Department of Cardi- 
ok?& F-25. The Cleveland Clinic Foundation. 9500 Euclid Avenue, Cleveland, 
Ohio 4419.5. 
W99b by the American cdlege of Cardiiay 
FWlshad hy Elsevies Science Inc. 
httracoronary stents. Studies were separated into those reporting 
stents placed emergently or electively witbout adjunct bigb- 
pressure halloon inflations, stems placed in sapbenous vein graft 
conduits, and steuts placed witb bii-pressure balloon htflations 
but without subsequent oral anticoagulants. Overall, subacute 
thrombosis was substantially bigber iu stents placed emergently 
(10.1%) compared to those placed etectively (4.3%). Among con- 
temporary trials employing high-pressure balloon inflations, tbe 
rate of stent thrombosis appears markedly lower (1.3%) despite 
reduced postprocedural nticoagulation. Taken together, these 
studies uggest factors associated titb a beigbtened risk of stent 
thrombosis, many of which can he avoided with proper case 
selection and contemporary techniques. 
(J Am coo Glniiol3996:27:494-503) 
coronary syndromes, are believed to be key contributors to 
stent thrombosis. A principal factor thought to be responsible 
for the high stent thrombosis rate during the early stent 
experience w3s inadequacy of anticoagulation and antiplatelet 
therapy (2). In a randomized study of 42 dogs, Palmaz and 
colleagues (3) reported that platelet deposition was lowest on 
intravascular stents in the group treated with a combination of 
heparin, aspirin, dipyridamole, and dextran compared to dogs 
treated with heparin alone or heparin and aspirin. Likewise, an 
early clinical experience with the PalmazSchatz stent revealed 
that fewer than 1% of 174 patients who received oral antico- 
agulation developed subacute closure compared to 18% of 39 
patients who received only antiplatelet therapy (4). Conse- 
quently, intense anticoagulation regimens were established, 
including heparin, dextran, aspirin, dipyridamole and warfarin. 
Not surprisingly, this engendered a substantial increase in 
bleeding complications. More recently, technical factors asso- 
ciated with stent deployment and proper vessel selection are 
believed to be of greater importance to stent thrombosis than 
adequacy of anticoagulation. Current stent deployment tech- 
niques appear to have markedly reduced the relative risk of 
thrombosis. This paper reviews factors associated with stent 
thrombosis and contemporary preventive strategies. 
hidence 
Initial series of stent placement (2,4) reported a disappoint- 
ingly high (-25%) occurrence of thrombotic stent closure. 
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Table 1. Subacute Stenl Thrombosis After Elective Stem Placement 
Fiat Author 
or Trial 
Name (ref no.) 
No. of 
Year Patients stem 
Cross-Sectional Studies 
Sehatz (4) 
Carrom (6) 
Fajadet (8) 
Nath (7) 
Khnura (9) 
Sutton (1 I) 
S-wF (5) 
E&+**t (13) 
FO!JV (25) 
Whi’fow (26) 
Pooled 
1991 226 
1992 220 
1992 282 
1993 14 
1993 74 
I994 224 
I994 3wJ 
1994 92* 
1994 99 
1994 244 
1991-1994 1,175 
P/S 
P/S 
P/S 
G!R 
PiS 
G/R 
P/S 
Mixed 
P/S 
Wiktor 
Mhd 
Tlvomhosis 
(no. (%] of 
patients) 
8 (3.7) 
I (0.5) 
13 (4.6) 
4 (28.6) 
l(l.4) 
8 (3.6) 
14 (4.7) 
5 (5.4) 
l(l.0) 
24 (9.8) 
79 (4.5) 
Randomized Trials 
STRESS (26) :994 205 PiS 7 (3.4) 
BENESTENT 1994 259 PiS 9 (3.5) 
(27) 
TASC f(28) 1994 133 P/s 6 (4.5) 
Pooled 1994 591 P/S 22 (3.7) 
‘Number of stentc BENESTENT = Belgium and Netherlands Stent Study 
Group; G/R = Gianmturco-Roubin; P/S = Pahaaz-Schatz; ref = reference: 
STRESS = Stent RFStenosis Study Group; TASC I = Trial of Angioplasty and 
Stents in Canada. 
Subsequent studies have been progressively more encouraging, 
with a range of subacute stent thrombosis from 0.5% lo 29% 
(pooled average 4.4%) (Table 1) (4-13), suggesting there was 
a period of learning for operators, improvement in stent 
deployment techniques and enhanced post-procedural care 
(4,7). Evidencing this, George et al. (14) estimated that the 
rate of stent thrombosis in their series of patients treated for 
threatened vessel closure was 12% from September 1988 to 
March 1990,11% from March 1990 to September 1990 and 5% 
from September 1990 to June 1991. More recently, in the 
STRESS (STent REStenosis Study) siudy (!S) in which 410 
patients were randomized to receive either stents or conven- 
tional balloon angioplasty, the incidence of subacute stent 
thrombosis was even lower (3.4%). In fact, although the 
sample size is small, this low rate of subacute stent thrombosis 
was not statistically different from the abrupt vessel closure 
rate among patients undergoing balloon angioplasty (1.5%). 
Similarly designed prospective studies, the BENESTENT 
(BElgium and NEtherlands STENT) Study Group (n = 520) 
(16) and TAX 1 (Trial of Angioplasty and Stents in Canada, 
n = 266) (17), corroborated this observation with rates of 
subacute stent thrombosis of 3.5% and 4.5%, respectively. 
Subacute stent thrombosis rate’s continue to decrease, and 
current efforts are targeting a rate of al%. 
Timing 
Acute stent thrombo& usually occurs within minutes to 
hours, whereas subacute stent thrombosis occurs within days to 
weeks after stent deployment (7). Stent thrombosis rarely 
occurs acutely, i.e., within the first 1-4 h following stent 
placement. When results of nine studies (4,6,7,1Y-23), includ- 
ing 1,383 patients, are pooled, only 8 (0.6%) episodes of acute 
stent thrombosis were reported, whereas there were 89 (6.4%) 
episodes of subacute Ihrombotic stent closure. Patients with 
acute stent thrombosis are usually still in the hospital and 
frankly symptomatic. Thus, they are quickly diagnosed and 
treated. On the other hand, subacute stent thrombosis, which 
represents the majority of thrombotic stent closure, can be 
somewhat insidious, occurring in patients 2 to 30 days follow- 
ing stent placement. Schiimig and colleagues (24) observed 
that 43% of patients with subacute stent thrombosis present 
within the first week, and over 80% by the second week. The 
modal presentation was between days 5 and 6 following stent 
placement (7,lS). Because many patients with subacute stent 
thrombosis have been discharged from the hospital, rapid 
restoration of coronary arterial flow is often not possible, and 
patients may sustain acute myocardral infarction or even death. 
Indeed, pooled data from numerous trials show rates of 
myocardial infarction and death following stent thrombosis 
of 61% and 12%. respectively. Therefore, the management of 
stent thrombosis requires rapid restoration of antegrade flow 
mechanically (emergency bypass surgery or angioplasty) or 
pharmacologically (thrombolytic therapy). 
Factors Associated With Steat Thrombosis 
Similar to the formative years of balloon angioplasty, much 
of the early understanding of stent thrombosis has been 
obtained fro,m re!rospective studies and registry data, although 
recent insight is emerging from prospective randomized trials. 
A number of factors associated with stent thrombosis are being 
defined and can be broadly categorized as related to the 
patient, the lesion, the stent and the technique of deployment 
(Fig. 1). 
Patient-related factors. The risk for subacute stent throm- 
bosis is related to several patient-specific factors such as 
clinical presentation (stable angina vs. acute coronary v- 
drome) and hemodynamic stability (coronary perfusion pres- 
sure and flow). In these different cliiical subsets of patients, 
there may be varied potential of thrombogenicity and resultant 
subacute stent thrombosis. 
Inalicatim for dent ffeploynent. Intracoronary stems may be 
deployed electively (4-13) (Table 1) or as a “bail-out” proce- 
dure during threatened or abrupt vessel closure (6-14,18- 
21,24-34) (Table 2). Stents may also be placed e!ectively to 
reduce restenosis (15.16) or as an,adjunct therapy to improve 
suboptimal angioplasty results (l&29,31,34,35). ‘fbe pooled 
rate of subacute stent thrombosis following elective stent 
deployment in 598 patients in the STRESS (U), BENESTENT 
(16) and TASC I (17) studies was 3.7%. These results were 
obtained in hemodynamically stable patients with lesions that 
were discrete in large, nontortuous native vessels, without the 
presence of intraluminal thrombus or involvement of ostium or 
bifurcation. 
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w Figure 1. Schematic diagram showing factors related to 
subacute stent th-ombosis. 
The observed occurrence of subacute stent thrombosis has surgery or myocardial infarction during the hospitalization 
been substantially higher when stcnts were deployed emer- period, though one patient had late stent occlusion. Larger 
gently, i.e., during threatened or abrupt vessel closure. Under studies have reported the incidence of subacute stent throm- 
these circumstances, the intravascular milieu can be highly bosis in the setting of threatened or acute vessel closure to 
thrombogenic from impaired blood flow. vessel wall dissection, range from 2% to 36% with a pooled mean of 10.1% (Table 2). 
subintimal hemorrhage, vasoconstriction, and platelet and Foley and colleagues (25) found that the incidence of subacute 
coagulation factor activation (35). Sigwart et al. (27) were first stent thrombosis in 99 patients with elective and 6t” patients 
to report the implantation of stents in 11 patients for abrupt with emergency stent placement was 1% and 12%, respec- 
closure complicating angioplasty. Contrary to what was ex- tively. In fact, most reports (7,22,23,36,3?) confirm the severai- 
petted, there were no deaths, emergent coronary bypass fold heightened occurrence of stent thrombosis when stems 
Table 2. Subacute Stent Thrombosis After Emergency Placement 
Sequelac of patients with stem thrombosis 
Fast Author 
(ref no.) 
Sigwan (27) 
de Feyter (28) 
Hat& (29) 
Roubin (18) 
Hemnann (21) 
Fajadet (8) 
Nath (7) 
Kimura (9) 
Heara ( 10) 
Colombo (19) 
Geotge (14) 
Maiello (30) 
Litlcoff (31) 
vrollu (20) 
Sutton (1 I) 
F.eckh0u1(13) 
WeY (25) 
Sch&nig (24) 
Whitlow (26) 
Metz (32) 
Hamm (33) 
PO&d 
YGU 
1988 
1990 
1991 
1992 
1992 
1992 
1993 
1993 
1993 
1993 
1993 
I993 
1993 
I994 
I994 
1994 
1994 
1994 
1994 
1994 
1994 
19884994 
No. of 
Patien’; 
I1 
IS 
IS 
III 
55 
145 
36 
23 
IO3 
S6 
494 
32 
61 
s9 
41s 
38 
60 
301 
14s 
101 
64 
I-928 
stem 
Wall 
Wall 
PYj 
G/R 
P/S 
P/S 
G/R 
P/S 
G/R 
P/S 
G/R 
P/S 
G/R 
Wiktor 
G/R 
Mixed 
P/S 
PIS 
Wiktor 
Mixed 
Strecker 
Mixed 
Tbromlwsis 
(no. [VI of patients) 
l(9.1) 
1 (6.7) 
I (6.7) 
9 (8.4) 
9Q6.4) 
18 (12.4) 
13 (36.1) 
3 (13.0) 
9 (X.1) 
l(l.9) 
43 (X.7) 
I(3.3) 
7(ll.S) 
IO (16.9) 
28 (6.7) 
6(I5.8) 
7 (11.6) 
21 (7.0) 
14 (9.7) 
8 (7.9) 
12(IY.X) 
194 (10.1) 
(no. (al of patients)* 
Myocardial Infarction Revarcularization 
1(100, I (loo) 
1 (mo) 0 
0 0 
5 (SS) 9 (100) 
8 (89) 3 W) 
NA NA 
NA NA 
NA NA 
4 w 3 (33) 
1 (Ice) 0 
20 (47) 2 ’1(67) 
0 I (Iuo) 
3 (43) 3 (43) 
NA 5 (SO) 
?I (75) NA 
3 (SO) 3 (SO) 
7(1Ou) 7 (loo) 
I2 (57) f9(9w 
9 w 5 (36) 
NA NA 
8 (67) 4 (33) 
103 (61) 93 (61) 
Death 
0 
0 
0 
0 
1(11) 
NA 
NA 
NA 
IUI) 
0 
2 (5) 
0 
2 (29) 
2(H)) 
2;:) 
0 
4(19) 
2 (14) 
NA 
NA 
16(12) 
*Each patient may have more than one end point reported. NA = data not available; other abbreviations a  in Table I. 
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are implanted as a “bail-out” compared to elective stent 2,O m m  was 7.9%. 8.7% and 25%, respectively. Similarly, 
placement, especially if the indication is complete vessel Roubin et al. (18) found that 2.5-mm stems, which represented 
closure. 47% of their stem population, accounted for 77% cases of 
Clinical pnwntarion. Acute coronary syndromes are com- subacute stent thrombosis. Because of this, most operators will 
manly associated with intracoronary thrombus (38,399. Intu- not electively place stents in vessels C3.0 m m  (44,459. In fact, 
itively, stent placement in patients with acute myocardial in recent randomized trials of balloon angioplasty versus 
infarction or unstable angina may present a higher risk for stents, vessels C3.0 m m  in diameter hy visual estimation were 
stent thrombosii compared to patients with chronic stable excluded (15,169. On the other hand, the investigators of the 
angina. Likewise, hemodynamically unstable patients with re- STRESS trial (45) reported their experience with stent place- 
duced coronary perfusion pressure may be at increased risk for ment in vessels slightly ~3.0 m m  (n = 1139, measured by 
intrastent thrombus formation. Indeed. in the first clinical quantitative coronary angiography. Interestingly, the restenosis 
report of self-expanding stems (Wallstent), patients with acute rate was lower in this group of patients with stems compared to 
coronary syndromes were more likely to develop subacute conventional balloon angioplasty alone while maintaining an 
stent thrombosis (2). Of the 25 patients who developed stent incidence of subacute stent thrombosis lower than in most 
thrombosis, 5 had conditions associated with increased throm- earlier studies. Overall, vessel size ~3.0 m m  remains a key 
bogenicity-unstable angina, myocardial infarction and predictor of stent thrombosis. 
chronic occlusion. Malosky et al. (40) reported that stent Lesion chamcteristics and morphdog)? Angiographic char- 
thrombosis occurred in 4.2% of 48 patients with and 1.8% of acteristics such as lesion eccentricity (7). degree of stenosis 
57 patients without unstable angina pectoris. Using multiple (7,229, ostial involvement (469, presence of intracoronaty 
logistic regression analysis in a statistical model consisting of thrombus and total occlusion may be associated with Ihe 
several clinical and angiographic factors, Nath and colleagues occurrence of subacute stent thrombosis. Stent thrombosis is 
(7) reported the risk of subacute stent thrombosis to be 11 more likely to occur in vessels with poor distal runoff, presence 
times higher for patients with unstable angina. However, a of collateral supply or vessels upplying akinetic or severely 
recent small retrospective analysis (41) suggests that the rate of hypokinetic myosardium (2). Lesions with greater degree of 
subazu!e stent thrombosis is not significantly higher in patients preprocedural stenosis usually have greater plaque burden or, 
with unstable angina. The reasons for these conflicting reports alternatively, may have occult laminar thrombus. Greater 
include different patient cohorts, procedural techniques and plaque burden may require debulking or greater vessel disten- 
indications. The reported incidence of subacute stent throm- sion to obtain an optimal result, possibly resulting in more 
bosis does vary with different indications for stent placement, vessel disruption and a more thrombogenic milieu, thereby 
even among patients with acute coronary syndromes. For increasing the risk for stent thrombosis (22). Furthermore, in 
example, Iyer et al. (42) deployed stents emergently in 46 severely diseased vessels, the atherosclerotic plaque may pro- 
patients within 16 days of myocardial infarction for acute or lapse through stent struts or articulation sites, increasing the 
threatened vessel closure complicating bslloon angioplasty, risk for thrombosis. 
and 5 patients (10.9%) developed subacute stent thrombosis. It has been generally held that one of the most important 
On the other hand, Marco et al. (43) deployed stents electively morphologic characteristics associated with subacute stent 
in 36 patients with recent (0 to 15 days) myocardial infarction, thrombosis is the presence of intracoronaty thrombus before 
and only 2 patients (5.6%) developed subacute stent thrombo- or after coronary intervention (7). Implanting a foreign body in 
sis. Thus. in general, stent placement in patients with acute the presence of thrombus may serve as a nidus for clot 
coronary syndromes need not be totally avoided, but should be propagation. Of 1,054 lesions treated with stents in two large 
approached cautiously. Risk of subacute stent thrombosis is studies, intracoronary thrombus was angiographically evident 
likely reduced by careful selection of patients. in 284 (27%) (14,479. The incidence of subacute stent throm- 
Lesion-related factors. The coronary anatomy and angio- bosis among patients with identifiable thrombus was 11%. 
graphic characteristics of each lesion are important determi- compared to 7% for those without. Unfortunately, angiogra- 
nants of subacute stent thrombosis. Some covariates can be phy lacks sensitivity in the identification of thrombus, and 
assessed objectively, such as vessel size, lesion location and other means of visualization, such as intravascular ultrasound 
length, but others are limited by angiography, such as the or angioscopy, may be needed to determine more accurately 
presence of intracoronary thrombus. the relative risk of subacute stent thrombosis from lesion- 
l+sse/ size. A key observation from the early experience of related thrombus. 
stent implantation was the relationship of stem thrombosis to Percutaneous recanalixation of totally occluded vessels is 
the size of the target vessel. The likelihood of developing associated with lower success and increased adverse events 
subacute stent thrombosis is inversely proportional to the with conventional angioplasty. Because the incidence of reclo- 
reference segment diameter-higher rates of thrombosis in sure is relatively higher following percutaneous revasculariza- 
smaller vessels (2)--probably as a result of less blood flow and tion of these lesions, it is not surprising that the risk of 
greater amount of metal per luminal area (7,329. Of 210 subacute stent thrombosis is also increased. Bilodeau et al. (48) 
patients reported by George et al. (149, the occurrence of reported a subacute thrombotic closure rate of 16% following 
subacute stent thrombosis for stents 53.0 mm, 2.5 m m  and balloon angioplasty with adjunctive stent’placement in totally 
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occluded vessels. However,‘most of the stems were placed in 
patients with cimsomitant threatened or abrupt vessel closure. 
Qpposing data from a small study by Almagor and colleagues 
(49) showed that only 2 (3.1%) of 65 patients had clinically 
manifest subacute stent thrombosis after elective stent place- 
ment in chronic totally occluded vessels. Therefore, stent 
placement in well selected patients with totally occluded 
vessels may not increase the risk of symptomatic subacute stem 
thrombosis excessively. Conversely, stem thrombosis may be 
underestimated among these patients because reocclusion may 
occur without symptoms. 
Coronary artery dissection during stent deployment is also 
associated with increased risk for subacute stent thrombosis 
(22,!Xt) (Fig. 1). In the STRESS study (22). 211 patients 
received stents electively (per protocol) or as a bail-out pro- 
cedure (crossover from the balloon angioplasty group). Of the 
10 patients who developed subacute stent thrombosis, 40% had 
coronary dissection evident at fmal angiography compared to 
only 9.5% of remaining 201 stem-treated patients. 
Site of stent placement. Schomig et al. (24) evaluated the 
risk of thrombosis following stent placement in different 
epicardial arteries among 339 patients. The risk of subacute 
stent thrombosis was lowest in the right coronary artery (2.9%) 
compared to the left anterior descending artery (10.1%) and 
the left circumflex artery (7.9%). On a multiple logistic regres- 
sion model on 243 consecutive stent placements, deployment 
in the left anterior descending or left circumflex arteries was a 
determinant for subacute stent thrombosis (51). The lower risk 
for stent thrombosis in the right coronary artery could be 
related to more streamline flow characteristics from the lack of 
major proximal branches and tortuosity. Although the left 
anterior descending artery has the highest reported risk for 
subacute stent thrombosis, other investigators found that the 
excessive risk was attributable to more frequent deployment as 
a bail-out procedure (52). Therefore, it remains uncertain 
whether the site of stent placement in the native coronary 
circulation substantially affects the risk for subacute stent 
thrombosis. 
Suphenous vein grafrs. Percutaneous revascularization of 
saphenous venous grafts is associated with higher risk and less 
favorable long-term results when compared to percutaneous 
treatment of native coronary vessels (53). Placement of stents 
in vein grafts may improve results (Table 3) (26,51,54-62) with 
a relatively low (2.2%) risk for subacute stem thrombosis. 
&XTOS et al. (61) successfully implanted 159 stems in venous 
commits in 95 patients with threatened or acute conduit 
closure after balloon angioplasty. All stents were at least 
3.0 mm in diameter, and the majority were 4.0 mm. Repeat 
angiography performed 7 days following stent implantation 
demonstrated only 1 of the 88 conduits to be occluded. More 
recently, Rechavia et al. (62) reported that none of the 29 
patients with stents placed at aortoostial stenosis of vein grafts 
developed subacute stent thrombosis. The low incidence of 
subacute stent thrombosis following stent placement in vein 
grafts may be simply attributable to the large conduit size and 
the absence of branches. On the other hand, an important 
JACC Vol. 27, No. 2 
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TabJe 3. Subacute S+-ar Thrombosis n Saphenous Vein Grabs 
Fint Authur No. of lhmimis 
(ret no.) Year Patienb stem (no. [%I of patients) 
uhan (54) 19x9 13 Wall 0 
Leon (55) lW1 192 P3 2(1.1) 
& Scheerder (56) 1992 69 Wall 7(10.1) 
Stmmpf (5) IW? 26 P,S 1 (KU) 
Bernardi (58) Mu 33 P/3 0 
Slraus (12) I994 101 Wall x (%I,) 
whitknt (26) Iw4 32 Wiktor 0 
Eeckhout (51) lw4 2s Mind ? (2.1) 
Piata (SY) NW i?(X) p:s u 
Fenton (hl)) 1994 Iyx Pi3 I (0.S) 
Dorros (hl, 1994 95 G,W I (I.3 
Recha ia (62) lws ?Y P,3 0 
Pwlrd IW-1W.l l.(llh hlivcd 22 (2.2) 
Ahhrr\iations as in Tables I anJ 2. 
factor that needs to be considered before deployment of stents 
in vein grafts is the adequacy of downstream flow in the 
recipient vessel, or so-called “runoff.” Although the vein grafts 
may be large and without branches, the distal native circulation 
may be small and Diffusely diseased, thereby reducing blood 
flow through the stent. 
Broad classitication of lesion morphology may help assess 
the risk of subacute stent thrombosis following stent place- 
ment. Simply stated, the risk for subacute stent thrombosis 
might be higher in lesions with more complex lesion morphol- 
ogy (22). Applying the most commonly used system, the 
modified American College of Cardiology/American Heart 
Association classification (63) Foley et al. (25) found that 40% 
of patients who developed subacute stent thrombosis had 
lesions categorized as B2 or C, whereas only 12% of the 
patients not developing subacute stent thrombosis had the 
same categories. This study was limited to 60 patients with 
stents placed as a bail-out procedure. With recent decreasing 
rates of subacute stent thrombosis, broad classification of 
lesion morphology has not been reliably associated with risk of 
developing subacute stent thrombosis in retrospective qtudies 
(64). For safety reasons, large randomized trials (15.16) com- 
paring conventional balloon angioplasty to stent placement 
have thus far excluded patients with recent myocardial infarc- 
tion or complex lesions. 
Stent-related faetors. The length and number of stents 
placed in a lesion as well as the stent geometry were considered 
to affect the incidence of subacute stent thrombosis. Similarly, 
stent-specific features such as anticoagulant coatings and stent 
material may influence the rate of stent thrombosis (Fig. 1). 
Length and nunzber of stehts. The greater amount of metal 
present in longer or multiple stents may be more thrombo- 
genic. Limited comparative data are available for stents of 
differing lengths (4). Roubin et al. (18) reported successful 
deployment of stents of two different lengths in 115 patients. A 
short model (12 mm) was placed in 27 patients, and a long 
(20 mm) model was placed in 88 patients. In this single series, 
JACC Vol. 27. No. Z 
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all nine patients who developed subacute stent thrombosis 
received the longer stent (4). Multiple stents may be needed in 
very long lesions or cases of long dissections, thereby height- 
ening thrombotic potenticl. For this reason, only limited data 
are again available, because controlled studies have excluded 
lesions requiring multiple stents. Hemnann et al. (21) placed 
stents emergently in 56 patients, 11 of whom received multiple 
stents. The incidence of subacute stent thrombosis for patients 
receiving single and multiple stents was similarly high (16% vs. 
18%). More recently. Colombo et al. (19) used I38 stents in 56 
patients to treat acute or threatened clostire. Though 57% of 
the patients received multiple stents, none developed stent 
thrombosis. Several other investigations (7,14,25) have also 
concluded that multiple stent deployment was not associated 
with an increased risk of subacute stent thrombosis. An 
explanation, in some cases, might be that suboptimal results 
and persistent dissection are slightly more likely after single 
stent placement, and this may paradoxically increase the risk 
for subacute stent thrombosis (19.25). Overall, it is unlikely 
that the risk for subacute stent thrombosis increases ubstan- 
tially with multiple compared to single stents when they are 
meticulously deployed without excessive overlapping. 
Types of sfenrs. There are several types of commercially 
available intravascular stent designs and structures that pro- 
vide different profiles, radial strength, flexibility and perhaps 
thrombogenicity. Furthermore, the stent strut diameters, 
which vary from approximately 70 pm (Strecker and Palmaz- 
Schatz stents) to more than Ii5 pm (Gianturco-Roubin and 
Wiktor stents), may also affect thrombogenicity (65). Although 
no prospective randomized study of different stents is available 
to make a meaningful direct comparison, the ;tent thrombosis 
rate was not different among 81 Palmaz-Schatz (4%) 32 
Wiktor (3%), and 21 Gianturco-Roubin (0%) stents in a small 
retrospective study (66). When data from numerous previous 
studies were pooled (Tables l-3) the rate of subacute stent 
thrombosis appears lowest for Palmaz-Schatz (3.7%), followed 
by Gianturco-Roubin (7.9%), Wiktor (10.0%). Strecker 
(12.7%) (67) and Wallstent (13.1%). 
Stem material and coating. Most stents are made of stain- 
less steel (Palmaz-Schatz, Gianturco-Roubin and Wallstent) 
or tantalum (Wiktor and Strecker). Other materials, such as 
nitinol (an alloy of nickel and titanium) (68), are being tested 
for lower intrinsic stent thrombogenicityi Another potential 
method to reduce stent thrombosis is by coating the metallic 
struts. The coat could selectively alter characteristics by cov- 
ering the metal surface. neutralizing surface potential, optimiz- 
ing surface tension and may deliver pharmacologic agents (69). 
Heparin-bonded, polymer-coated stents were first shown to be 
effective in reducing thrombosis in rabbit (70) and pig (71) 
models. The pilot phase of the BENESTENT II trial evaluated 
the efficacy of this type of stent in 51 patients (72), and none 
develoned stent thrombosis. Local deliverv of nharmacoloeic 
1  d  #  
agents has been tested in different animal models with varying 
results. The usefulness and cost-benefit of such approaches 
remain to be evaluated in large-scale randomized trials. 
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khnique-related factors. Perhaps the greatest contribu- 
tion in preventing subacute stent thrombosis has been the 
improvement in stent deployment technique and poststent 
management. Serruys and DiMario’s (73) question, “Who was 
thrombogenic: the stent or the doctor?” was very appropriate. 
By defining optimal stent deployment, the requirements for 
anticoagulation and antiplatelet therapy appear to be quickly 
evolving (Fig. 1). 
Optimization of h-a- and postpnxeduml management. For 
over a decade, anticoagulation strategies have been studied in 
animal stent models in order to minimize the risk for stent- 
related thrombosis. In the first multicenter trial with the 
Palmu-Schatz stent (4), patients receiving aspirin but not 
warfarin experienced a severalfold higher rate of subacute 
stent thrombosis. In response, anticoagulation regimens were 
bolstered. Compared to conventional balloon angioplasty, 
improved angiographic and clinical outcomes following stent 
deployment were achieved at the cost of a substantial increase 
in hemorrhagic complications (ranglug from 5% to 30%). 
which substantially increased length of hospitalization and cost 
(15,16). 
With the aid of intravascular ultrasound imaging, it appears 
that when stents are deployed with struts well apposed to the 
vessel wall and in full expansion (yielding an optimally large 
luminal area), the need for anticoagulation is diminished. 
Following standard balloon inflation pressure of 6-8 atmo- 
spheres, Goldberg and colleagues (74) found that only 5 (13%) 
of 40 patients had adequate stent expansion as assessed by 
ultrasound despite an acceptable angiographic appearance. 
Additional balloon inflations with higher pressure and some- 
times with a larger balloon diameters were required to obtain 
satisfactory ultrasound results (74-76). Although some inves- 
tigators (75,77) have used empirically high balloon inflaticcs 
pressure of 212 atmospheres to achieve an optimal luminal 
area, others have suggested using a combined intravascular 
ultrasound and balloon catheter approach, which was devel- 
oped to enable rapid determination of adequate stent deploy- 
ment (78). 
The evolving paradigm of minimizing stent thrombosis 
focuses on obiaining optimal stent deployment rather than the 
intrinsic thrombogenic surface of stents (73). Because platelets 
have been shown to be the primary component of stent 
thrombosis (79) with optimal stent deployment, antiplatelet 
therapy should be sufficient to prevent stent thrombosis during 
neointimal coverage. The efficacy of using antiplatelet agents 
alone after stent placement was first demonstrated by Co- 
lombo and colleagues (76). Of 359 stent-treated patients, 321 
(89%) received only antiplatelet therapy (aspirin t ticlodig 
ine) after optimal stent deployment with ultrasonic guidance. 
Only three cases (0.9%) of stent thrombosis occurred At 
angiographic follow-up, two additional episodes of stem clo- 
sure were noted at 3 and 4 months. An ongoing multicenter 
trial, MUSIC (Multicentre Ultrasound Study In Coronaries). is 
evaluating the ultrasound criteria proposed by Colombo and 
colleagues. Cumulatively, 2,630 patients have been reportedly 
treated with at least 3,141 stems using antiplatelet agents 
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Table 4. Subacute Stent Thrombosis Without Oral Anticoagulation 
First Author No. of Throminsis 
(ret Ito.) YGU Pdtients stent Aspirin Ticlopidinc 1viJs (no. I’/;] of patients) 
Elias’ (80) 
Aubry’ (81) 
Bleqbo (82) 
Ml&c* (83) 
Carvalho’ (%I) 
Jordan’ (85) 
Jordan* (85) 
Barragan’ (W, 
Colomho (76) 
Blasini (87) 
Colomtm (xx) 
Rusk (KY) 
Wonp (W) 
Lahlimchc (91) 
Barragan (9:) 
Fajadet (Y3) 
van Belle (94) 
Schuhlen (Y5) 
Culombn (96) 
corcos (97) 
Tresukosol (98) 
Savallr (99) 
Mattor (ItHI) 
Lef?vre (101) 
Pcalcd 
I994 79 Wiktor + + l(l.3) 
1994 80 Mixed + i 2 (2.5) 
1994 74 Misd 2 0 
1993 397 Mixed + + 6 (1.5) 
1994 87 G/R + + I (!.I) 
19?H I32 P/S + + U 
1994 87 G/R f + I(l.1) 
I ‘YY4 23x Mivzd I IO (J.?) 
lY9S 321 P/S + 2 & 3 (n.li; 
19% hU Pr’S + + I) 
19% 64) GIR + 2 in 0 
19% ?7 P,S + + t 1) 
199s 33 NA t NA t- 0 
IY95 9x Mixed + + 0 
lYY5 ?UX Mixed + t -f I (0.5) 
19Y5 119 P/S t + I (0.X) 
I YY5 53 Mixed + + 0 
IW Ml NA + + + 0 
19% 5’) Wiktor + NA + l(l.5) 
I99S lo(1 Mixed + + I (U\) 
1995 33 MS i z (h.U) 
1995 6lJ Mixed + 2 (3.1) 
IYYS 46 Mixed + + + 0 
lY95 150 P/S t + I ((1.X) 
1YY4-IYYS ?.hY) Mixed t + i 33 (1.3) 
‘Low-molmlar weight hcparic ui is used for ? IO 4 eceks after the prcxcdurs. IVUS = intravascular ultrax)u,und; 
MS = Micrustent; t = used: - = not used; i = used in some patients; other ahbreuiations as in Tahlcr I and 3. 
without warfarin, and remarkably, only 33 (1.3%) have devel- 
oped stem thrombosis (Table 4) (76,80-101). Interestingly, 
more than two-thirds of these patients did not have intravas- 
cular ultrasound imaging. 
The preliminary results of these numerous recent trials 
(Table 4) @O-86,91,93,94,97-99,101) are very encouraging 
and will likely be confirmed by larger nulticenter trials. In 
addition to studies addressing the importance of ultrasound- 
guided stent deployment, other methods such as on-line video 
densitometry with enhancement of radio-opacity of stent struts 
to define adequate stent deployment are being investigated. 
Finally, the concomitant need for ticlodipine with aspirin is 
also being studied in a multicenter trial, MUST (MUlticentse 
Stent Ticlodipine). Ticlodipine is costly and has several impor- 
tant side effects such as neutropenia, thrombocytopenia and 
skin rash (102). Therefore, it is suggested that white blood cell 
and platelet counts be performed every 2 weeks for the first 3 
months. Many operators are currently prescribing ticlodipine 
for only 1 month, the time needed for neointimal coverage of 
the stent surface. Colombo et al. (76) reported that side effects 
requiring medication discontinuation was more common in the 
2.52 patients treated with ticlodipine (2.8%) than the 69 
patients treated with aspirin alone (0%). Although the rate of 
stent thrombosis was not significantly different between the 
aspirin and aspirin with ticlodipine groups, early results from 
two other clinical trials (Table 4) (97,98) not using intravascu- 
la: ultrasound suggested a slightly higher rate of stent throm- 
bosis in patients treated with aspirin alone. 
Summary 
A substantial increase in the understanding of stent throm- 
bosis has taken place over the past several years. The rapidly 
changing concepts of stent thrombosis can be liktined to the 
early years of balloon angioplasty, when a higher rate of abrupt 
vessel closure initially occurred. Early stent studies demon- 
strated a relatively high rate of stent thrombosis that was 
somewhat improved with aggressive anticoagulation. Subse- 
quent studies have shown an improved outcome with careful 
patient selection. Although concern for stent thrombosis 
remains-especially in small vessels, in the setting of abrupt 
vessel closure, in the presence of intracoronary thrombus or an 
acute coronary syndrome-contemporary data are encourag- 
ing even with reduced anticoagulation. Recent prospective 
trials have shown, in fact, that by careful case selection, 3% 
could be an achievable rate of subacute stem thrombosis. 
Further advances employing high-pressure poststent inflation 
(16-18 atmospheres) and intravascular ultrasound imaging 
promise subacute stent thrombosis rates of &I%, with anti- 
platelet therapy alone. Current trials exploring the use of 
aspirin alone (STRESS III), heparin-coated sterns (BENE- 
STENT II) and conjunctive use of platelet glycoprotein fib/ 
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IIIa inhibitors (EPILOG, Evaluation in PTCA to Improve 
Long-term Outcome with Giycoprotein IIb/IlIa blockade) may 
lead to strategies that farther reduce the rate of stent throm- 
bosis, perhaps even in the setting of acute myocardiai infarc- 
tion. 
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